All Stories

  1. Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

    Article • European Journal of Cancer, March 2021, Elsevier

    Eva Germovsek

  2. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings

    Article • mAbs, January 2021, Taylor & Francis

    Eva Germovsek

  3. A Time‐to‐Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

    Article • Clinical Pharmacology & Therapeutics, September 2020, Wiley

    Eva Germovsek

  4. Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations

    Article • Clinical Pharmacology & Therapeutics, September 2019, Wiley

    Eva Germovsek

  5. A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients

    Article • The AAPS Journal, April 2019, Springer Science + Business Media

    Eva Germovsek

  6. Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data

    Article • Journal of Antimicrobial Chemotherapy, January 2019, Oxford University Press (OUP)

    Eva Germovsek

  7. Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance

    Article • Clinical Pharmacokinetics, December 2018, Springer Science + Business Media

    Eva Germovsek

  8. Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance

    Article • Clinical Pharmacokinetics, April 2018, Springer Science + Business Media

    Eva Germovsek

  9. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

    Article • Journal of Antimicrobial Chemotherapy, April 2018, Oxford University Press (OUP)

    Eva Germovsek

  10. Pharmacokinetics of Penicillin G in Preterm and Term Neonates

    Article • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals

    Eva Germovsek, Hiie Soeorg

  11. Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

    Article • British Journal of Clinical Pharmacology, December 2016, Wiley

    Eva Germovsek

  12. What do I need to know about aminoglycoside antibiotics?

    Article • Archives of Disease in Childhood Education & Practice, August 2016, BMJ

    Eva Germovsek

  13. What do I need to know about penicillin antibiotics?

    Article • Archives of Disease in Childhood Education & Practice, July 2016, BMJ

    Eva Germovsek

  14. Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants

    Article • Antimicrobial Agents and Chemotherapy, June 2016, ASM Journals

    Eva Germovsek

  15. G394 Optimisation of vancomycin dosing regimen in newborns by performing a population pharmacokinetic analysis of prospectively collected data

    Article • Archives of Disease in Childhood, April 2016, BMJ

    Eva Germovsek

  16. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology

    Article • Advanced Drug Delivery Reviews, June 2014, Elsevier

    Eva Germovsek

  17. Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates

    Article • Antimicrobial Agents and Chemotherapy, June 2012, ASM Journals

    Eva Germovsek